- Home
- BLRX vs BFRI Comparison
BLRX vs BFRI Comparison
Compare BLRX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | BFRI |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | Israel | United States |
| Employees | N/A | 94 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.2M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | BFRI |
|---|---|---|
| Price | $3.10 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $2.75 |
| AVG Volume (30 Days) | 22.9K | ★ 154.0K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.54 |
| 52 Week High | $7.77 | $1.19 |
Technical Indicators
Market Signals| Indicator | BLRX | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 60.68 | 37.39 |
| Support Level | $2.66 | $0.79 |
| Resistance Level | $3.11 | $1.06 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 72.00 | 11.18 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.